Joel Peacock, MD
Adult Medicine · Aurora, CONPI 1437223054
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,023 and has fallen 65.3% since, to $355 in 2025.
Across 150 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$301
- Pfizer$253
- AbbVie$198
- Lilly USA, LLC$178
- Novo Nordisk$175
- Novartis$163
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,750100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 15 | $301 |
| Pfizer | 15 | $253 |
| AbbVie(2 entities) | 9 | $198 |
| Lilly USA, LLC | 10 | $178 |
| Novo Nordisk | 10 | $175 |
| Novartis | 10 | $163 |
| Sunovion Pharmaceuticals Inc. | 9 | $145 |
| Neurocrine Biosciences, Inc. | 7 | $145 |
| Sumitomo Pharma America, Inc. | 5 | $98 |
| Amgen | 4 | $81 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Boehringer Ingelheim | 4 | $72 |
| Exact Sciences | 4 | $65 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| AstraZeneca(2 entities) | 4 | $60 |
| Astellas Pharma US Inc | 3 | $54 |
| Acadia Pharmaceuticals Inc | 2 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $51 |
| Dexcom, Inc. | 2 | $49 |
| Merck | 3 | $47 |
| GSK | 2 | $47 |
| Lundbeck LLC | 2 | $43 |
| Avanir Pharmaceuticals, Inc. | 3 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $35 |
| Abbott | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Inogen, Inc. | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Bayer | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $13 |
How this compares
Too few adult medicine providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $118,789 |
| XareltoRivaroxaban | 42 | $51,076 |
| OzempicSemaglutide | 24 | $33,550 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $31,680 |
| LinzessLinaclotide | 16 | $15,442 |
| MyrbetriqMirabegron | 12 | $14,197 |
| JanuviaSitagliptin Phosphate | 11 | $13,996 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $13,910 |
| JardianceEmpagliflozin | 13 | $11,317 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $9,641 |
| PremarinEstrogens, Conjugated | 15 | $8,349 |
| Levothyroxine Sodium | 372 | $4,845 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $3,489 |
| Atorvastatin Calcium | 388 | $3,095 |
| Omeprazole | 151 | $3,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $253 | $127,13894 claims |
| Johnson & JohnsonXarelto | $301 | $51,07642 claims |
| Novo NordiskOzempic | $175 | $33,55024 claims |
| GSKTrelegy Ellipta | $47 | $31,68024 claims |
| AbbVieLinzess, Namzaric | $198 | $25,08328 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $14,19712 claims |
| MerckJanuvia | $47 | $13,99611 claims |
| Boehringer IngelheimJardiance | $72 | $11,31713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other adult medicine in Aurora
- Madeleleine BrownAurora$731
- Claire Diamant-YefetCentennial$5K
- Ashley HillikerDelta$2K
- Julie KinklerSteamboat Springs$1K
- Erin HameroffEnglewood$1K
- Alexis ParkerDenver$1K
- Rodney MuhammadColorado Springs$465
- Tara RechtenbaughEnglewood$142
- Shelly JolesColorado Springs$125
- Susan EmersonBoulder$69
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.